Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| MD MDNAFMedicenna Therapeutics | $0.29-2.0% | $26.9M | 3 assetsPhase 2b | MDNA11 (IL-2)Phase 1/2 · Data readout | |
| MD MDWDMediWound | $13.21+0.7% | $170.5M | 5 assetsStage unavailable | No dated catalyst | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $3.07+10.4% |
| — |
4 assetsStage unavailable |
| No dated catalyst |
| ME MESOMesoblast | $17.00-2.5% | $2.20B | 8 assetsPhase 3 | RexlemestrocelPhase 3 · Data readout |
| MG MGNXMacroGenics | $4.10+0.7% | $261.2M | 17 assetsPhase 2 | MGC026Phase 1 · Data readout |
| MG MGTAMagenta Therapeutics | $0.70-7.7% | — | 2 assetsStage unavailable | No dated catalyst |
| MG MGTXMeiraGTx | $14.34-1.4% | $1.38B | 6 assetsPhase 2 | AAV2-hAQP1Phase 2 · Data readout |
| MI MIRAMira Pharmaceuticals | $0.76+4.6% | $32.1M | 3 assetsStage unavailable | No dated catalyst |
| MI MIRMMirum Pharmaceuticals | $96.31-0.8% | $5.87B | 10 assetsPDUFA | Zilurgisertib (ALK2 Inhibitor)PDUFA · Approval decision |
| MI MISTMilestone Pharmaceuticals | $1.06+2.4% | $131.3M | 4 assetsApproved | No dated catalyst |
| ML MLTXMoonLake Immunotherapies | $15.76-0.7% | $1.34B | 6 assetsPhase 3 | Sonelokimab Phase 3 · Data readout |
| ML MLYSMineralys Therapeutics | $25.65-0.4% | $2.27B | 3 assetsPDUFA | LorundrostatPDUFA · Approval decision |
| MN MNKDMannKind Corporation | $4.15-2.6% | $1.33B | 15 assetsApproved | No dated catalyst |
| MN MNOVMediciNova | $1.39+2.2% | $68.4M | 10 assetsPhase 2/3 | MN-001 (tipelukast)Phase 2 · Data readout |
| MN MNPRMonopar Therapeutics | $107.72-2.9% | $723.0M | 4 assetsStage unavailable | No dated catalyst |
| MO MOLNMolecular Partners | $4.40+4.0% | $165.0M | 6 assetsPhase 2 | MP0712 (212Pb x DLL3)Phase 1/2 · Data readout |
| MO MORMorphoSys AG | $18.96+0.0% | $2.86B | 6 assetsStage unavailable | No dated catalyst |
| MP MPLTMaplight Therapeutics | $11.21-0.2% | $519.9M | 3 assetsPhase 3 | ML-007C-MA (M1/M4 Agonist)Phase 2 · Data readout |
| MR MREOMereo BioPharma | $0.29-1.0% | $46.4M | 9 assetsStage unavailable | No dated catalyst |
| MR MRKMerck & Co | $152.55+2.4% | $376.37B | 96 assetsApproved | WELIREG/Belzutifan (MK-6482) + LENVIMA/Lenvatinib (E7080) (HIF-2α Combo)PDUFA · Approval decision |
| MR MRKRMarker Therapeutics | $1.39+13.9% | $23.2M | 4 assetsStage unavailable | No dated catalyst |
| MR MRNAModerna | $145.13+8.9% | $57.94B | 23 assetsPhase 3 | mRNA-1574Phase 1 · Data readout |
| MR MRNSMarinus Pharmaceuticals | $0.55+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| MR MRSNMersana Therapeutics | $29.08+0.0% | $145.4M | 5 assetsStage unavailable | No dated catalyst |
| MR MRTXMirati Therapeutics | $58.70+0.0% | $4.12B | 2 assetsStage unavailable | No dated catalyst |
| MR MRUSMerus | $90.00+0.0% | $6.83B | 7 assetsStage unavailable | No dated catalyst |
| MT MTEMMolecular Templates | $0.00+0.0% | — | 8 assetsStage unavailable | No dated catalyst |
| MT MTNBMatinas Biopharma | $0.20+8.9% | $2.9M | 2 assetsStage unavailable | No dated catalyst |
| MT MTSRMetsera | $70.50-0.4% | $7.43B | 4 assetsStage unavailable | No dated catalyst |
| MU MURAMural Oncology plc | $2.04+0.0% | $35.4M | 3 assetsStage unavailable | No dated catalyst |
| MY MYOVMyovant Sciences | $26.98-0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| N/ N/ABiomedical Meetings | — | — | 42 assetsBiomedical Meeting | World Conference on Lung Cancer (WCLC) Biomedical Meeting · Conference |
| NA NAMSNewAmsterdam Pharma Company NV | $27.87+0.3% | $3.26B | 8 assetsPhase 3 | ObicetrapibPhase 3 · Data readout |
| NB NBIXNeurocrine Biosciences | $152.57-0.2% | $15.51B | 25 assetsPhase 1 | NBIP-2118 (CRF2 Peptide Agonist)Phase 1 · Data readout |
| NB NBTXNanobiotix | $43.55-0.3% | $2.21B | 7 assetsPhase 3 | RT + NBTXR3 Phase 1 · Data readout |
| NC NCNANucana | $1.52-0.7% | $6.3M | 3 assetsPhase 1/2 | NUC-7738 (ProTide) +/- pembrolizumabPhase 1/2 · Data readout |
| NE NERVMinerva Neurosciences | $4.84+1.0% | $231.1M | 2 assetsPhase 3 | Roluperidone (5-HT2A antagonist)Phase 3 · Data readout |
| NE NEXINexImmune Inc | $0.00+0.0% | $139 | 2 assetsStage unavailable | No dated catalyst |
| NG NGM NGM Biopharmaceuticals | $1.54+0.0% | — | 9 assetsStage unavailable | No dated catalyst |
| NG NGNENeurogene Inc | $38.63+1.7% | $773.0M | 2 assetsPhase 3 | NGN-401 Phase 3 · Data readout |